Chapter 1. Executive Summary
Chapter 2. Scope of The Study
2.1. Market Definition
2.2. Scope of The Study
2.2.1. Objectives of Report
Chapter 3. Evolve BI Methodology
Chapter 4. Market Insights and Trends
4.1. Supply/ Value Chain Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitutes
4.2.5. Industry Rivalry
4.3. Impact of COVID-19 on Retinal Biologics Market
4.3.1. Impact on Market Size
4.3.2. End User Trend, Preferences and Budget Impact
4.3.3. Regulatory Framework/Government Policies
4.3.4. Key Players Strategy to Tackle Negative Impact
4.3.5. Opportunity Window
Chapter 5. Market Dynamics
5.1. Introduction
5.2. DRO Analysis
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Opportunities
Chapter 6. Global Retinal Biologics Market, By Drug Class
6.1. Introduction
6.2. TNF-α Inhibitor
6.3. VEGF-A Antagonist
Chapter 7. Global Retinal Biologics Market, By Retinal Disorder Type
7.1. Introduction
7.2. Age-related Macular Degeneration (AMD)
7.3. Diabetic Retinopathy (DR)
7.4. Diabetic Macular Edema (DME)
7.5. Macular Hole
7.6. Uveitis
7.7. Others
Chapter 8. Global Retinal Biologics Market, By Distribution Channel
8.1. Introduction
8.2. Hospitals
8.3. Retail Pharmacies
8.4. Specialty Ophthalmology Clinics
Chapter 9. Global Retinal Biologics Market, By Region
9.1. Introduction
9.2. North America
9.2.1. Introduction
9.2.2. Driving Factors, Opportunity Analyzed and Key Trends
9.2.3. Market Size and Forecast, By Country, 2020 - 2028
9.2.4. Market Size and Forecast, By Drug Class, 2020 - 2028
9.2.5. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.2.6. Market Size and Forecast, By Distribution Channel, 2020 – 2028
9.2.7. US
9.2.7.1. Introduction
9.2.7.2. Driving Factors, Opportunity Analyzed and Key Trends
9.2.7.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.2.7.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.2.7.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.2.8. Canada
9.2.8.1. Introduction
9.2.8.2. Driving Factors, Opportunity Analyzed and Key Trends
9.2.8.4. Market Size and Forecast, By Drug Class, 2020 - 2028
9.2.8.5. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.2.8.6. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.3. Europe
9.3.1. Introduction
9.3.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.3. Market Size and Forecast, By Country, 2020 - 2028
9.3.4. Market Size and Forecast, By Drug Class, 2020 - 2028
9.3.5. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.3.6. Market Size and Forecast, By Distribution Channel, 2020 – 2028
9.3.7. Germany
9.3.7.1. Introduction
9.3.7.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.7.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.3.7.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.3.7.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.3.8. France
9.3.8.1. Introduction
9.3.8.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.8.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.3.8.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.3.8.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.3.9. UK
9.3.9.1. Introduction
9.3.9.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.9.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.3.9.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.3.9.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.3.10. Italy
9.3.10.1. Introduction
9.3.10.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.10.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.3.10.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.3.10.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.3.11. Rest of Europe
9.3.11.1. Introduction
9.3.11.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.11.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.3.11.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.3.11.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.3. Market Size and Forecast, By Country, 2020 - 2028
9.4.4. Market Size and Forecast, By Drug Class, 2020 - 2028
9.4.5. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.4.7. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.4.8. China
9.4.8.1. Introduction
9.4.8.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.8.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.4.8.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.4.8.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.4.9. India
9.4.9.1. Introduction
9.4.9.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.9.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.4.9.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.4.9.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.4.10. Japan
9.4.10.1. Introduction
9.4.10.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.10.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.4.10.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.4.10.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.4.11. South Korea
9.4.11.1. Introduction
9.4.11.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.11.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.4.11.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.4.11.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.4.12. Rest of Asia-Pacific
9.4.11.1. Introduction
9.4.12.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.12.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.4.12.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.4.12.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.5. Rest of The World (RoW)
9.5.1. Introduction
9.5.2. Driving Factors, Opportunity Analyzed and Key Trends
9.5.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.5.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.5.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.5.6. Market Size and Forecast, By Region, 2020 - 2028
9.5.7. South America
9.5.7.1. Introduction
9.5.7.2. Driving Factors, Opportunity Analyzed and Key Trends
9.5.7.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.5.7.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.5.7.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
9.5.8. Middle East & Africa
9.5.8.1. Introduction
9.5.8.2. Driving Factors, Opportunity Analyzed and Key Trends
9.5.8.3. Market Size and Forecast, By Drug Class, 2020 - 2028
9.5.8.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
9.5.8.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
Chapter 10. Competitive Landscape
10.1. Introduction
10.2. Vendor Share Analysis, 2020/Key Players Positioning 2020
Chapter 11. Company Profiles
11.1. Novartis AG
11.1.1. Business Overview
11.1.2. Financial Analysis
11.1.3. Product Portfolio
11.1.4. Recent Development and Strategies Adopted
11.1.5. SWOT Analysis
11.2. F. Hoffmann La Roche Ltd
11.2.1. Business Overview
11.2.2. Financial Analysis
11.2.3. Product Portfolio
11.2.4. Recent Development and Strategies Adopted
11.2.5. SWOT Analysis
11.3. AbbVie Inc.
11.3.1. Business Overview
11.3.2. Financial Analysis
11.3.3. Product Portfolio
11.3.4. Recent Development and Strategies Adopted
11.3.5. SWOT Analysis
11.4. MeiraGTx Limited
11.4.1. Business Overview
11.4.2. Financial Analysis
11.4.3. Product Portfolio
11.4.4. Recent Development and Strategies Adopted
11.4.5. SWOT Analysis
11.5. OncoGene
11.5.1. Business Overview
11.5.2. Financial Analysis
11.5.3. Product Portfolio
11.5.4. Recent Development and Strategies Adopted
11.5.5. SWOT Analysis
11.6. Johnson & Johnson
11.6.1. Business Overview
11.6.2. Financial Analysis
11.6.3. Product Portfolio
11.6.4. Recent Development and Strategies Adopted
11.6.5. SWOT Analysis
11.7. Allergan
11.7.1. Business Overview
11.7.2. Financial Analysis
11.7.3. Product Portfolio
11.7.4. Recent Development and Strategies Adopted
11.7.5. SWOT Analysis
11.8. Bristol-Myers Squibb Company
11.8.1. Business Overview
11.8.2. Financial Analysis
11.8.3. Product Portfolio
11.8.4. Recent Development and Strategies Adopted
11.8.5. SWOT Analysis
11.9. Regeneron
11.9.1. Business Overview
11.9.2. Financial Analysis
11.9.3. Product Portfolio
11.9.4. Recent Development and Strategies Adopted
11.9.5. SWOT Analysis
11.10. Oxurion NV
11.10.1. Business Overview
11.10.2. Financial Analysis
11.10.3. Product Portfolio
11.9.4. Recent Development and Strategies Adopted
11.9.5. SWOT Analysis
Chapter 12. Key Takeaways